IRDAI Reopens Commission Caps and Policybazaar Hits a Circuit

PB Fintech fell 20.01% to Rs 1,508.90 on September 24 after the insurance regulator proposed putting commission caps back on distributors. The Sensex was down 625.52 points, or 0.84%, at 74,202.73, and the Nifty was down 206.40 points, or 0.88%, at 23,240.40. That index print looked like a soft global tape. The stocks that actually broke were the ones that get paid to sell insurance.

IRDAI released a two-part consultation paper on September 23 titled Recalibrating Economics of Insurance Distribution. Three years after it scrapped product-level commission caps, the draft puts them back, tightens expense limits, and bans forced bundling of cover with loans. Comments run through October 25. The rules, if notified, would start in FY28.

The 2023 Cap Removal Comes Due

In 2023 IRDAI dropped product-level commission caps and moved insurers onto an overall expenses of management limit, set out later in the 2024 expenses of management circular. General insurers could spend up to 30% of gross premium, health insurers up to 35%, covering commissions and other costs. Boards were meant to police payouts. IRDAI now says that check did not hold.

The inability to exercise adequate cost discipline under the flexible EoM regime makes a compelling case for hard caps on commissions within revised EoM limits, stringent implementation, and enhanced regulatory oversight.

Insurance Regulatory and Development Authority of India, consultation paper, September 23, 2026

The paper says board approval of commission policy has often been a formality. For individual life products such as pure term, participating, non-participating savings and linked plans, average first-year commission among insurers ranged from 14% to 51% of premium, with a maximum from 33% to 81%. Agents and corporate agents, including banks, took 27% to 61% on average and as much as 34% to 92%. Those two channels account for about two-thirds of life business.

Credit life sold with housing or vehicle loans paid banks 5% to 41% on average and NBFCs 7% to 47%. General insurance averages ran 6% to 29%, with maxima of 32% to 93%. The regulator also said distributor payouts grew four to five times faster than gross premium between FY23 and FY25. India is the world’s 10th-largest insurance market, with premiums of Rs 11.93 trillion ($124.42 billion) in FY25 and about 60 insurers.

THE GLIDE PATH IN THE DRAFT

1. 2023: Product-level commission caps are removed and replaced with board-set EoM limits.
2. September 23, 2026: IRDAI publishes the two-part paper and asks for comments until October 25.
3. FY28: Proposed start. Life EoM would fall to 15% of gross direct premium within two years and 12.5% within five, with already-lean firms steered toward 10%. General EoM would move from 30% of gross written premium to 20% of domestic GDPI over five years, with 25% at two years.

Tied agents would keep higher first-year caps than banks, brokers and aggregators. For life policies of 10 years and above, agents would be capped at 25% in year one and 5% on renewal; other distributors at 20% and 3%. Health first-year payouts would be 15% for distribution entities and 20% for agents. New-vehicle motor third-party commission is proposed at 0% to 2.5%. Marketing support, brand fees, rewards and travel would sit inside the same statutory cap. Compulsory bundling of insurance with credit would be banned, as would collecting a phone number before a digital quote.

Why PB Fintech Hit a 20% Lower Circuit

Policybazaar’s parent opened at the 10% band and then printed a 20% lower circuit at Rs 1,508.90 against Wednesday’s close of Rs 1,886.30, after a 4.5% gain in the prior session. Turtlemint, another listed aggregator, was 20% lower at Rs 109.04. The draft hits the take-rate the platforms live on: health renewals and porting, first-year term life, and motor own-damage and third-party commissions.

Bernstein wrote that the proposed cuts are “ugly” and that it was wrong: “PB Fin’s unit-economics unravels at the proposed take-rate caps.” The desk flagged a call-centre-heavy cost base against halved health take-rates, deferred pure-term payouts, and third-party motor commissions near zero, plus the ban on capturing contacts before a quote. Macquarie said PB Fintech looks the most exposed name it covers, and that a 200 bps squeeze in take-rates could cut EBITDA by about 25%, all else equal. Jefferies said a 10% cut in new-business commission rates would translate into a 10% to 12% earnings drop for PB Fintech and Turtlemint, with little room for insurers to absorb the hit in operating costs.

Emkay Global said the proposals could redefine distribution economics and leave some models unviable if they are notified as drafted. The market is not suddenly doubting Policybazaar’s share of insurer broker pools. It is repricing the rupees those pools will still pay.

WHAT WE KNOW

• The document: A two-part public consultation, not a notified regulation, with feedback open until October 25, 2026.
• The start date: IRDAI has slated the framework for FY28 if it proceeds.
• The cluster: Aggregators, private life names with heavy banca, and lenders that sell credit-linked cover led the September 24 decline.

WHAT IS UNCONFIRMED

• Final caps: Industry comments can still change the percentages before a regulation is issued.
• Earnings math: Broker 10-12% and 25% EBITDA sketches assume the draft numbers stick and costs do not fall with them.

Dinesh Khara, the former State Bank of India chairman who earlier chaired an IRDAI reform panel, said a 20-25% near-term earnings hit at PB Fintech “maybe it might be the outcome in the immediate term,” but that wider reach should lift volumes later. Chairperson Ajay Seth’s authority is asking for comments, not collecting them as a formality. Broker notes also warn that a rollback looks unlikely given the data tables published with the draft.

Axis Bank, HDFC Bank and L&T Finance

Nifty Bank was at 55,583.20, down 1.71%. Nifty Financial Services led sector losses at 25,038.85, down 2.06%. That is the bancassurance line showing up in the index, not a generic bank scare. Macquarie and HSBC flagged Axis Bank and HDFC Bank as more exposed than SBI, ICICI Bank or Kotak Mahindra Bank because insurance fees are a larger slice of non-interest income. L&T Finance faces a proposed 2.5% cap on loan-bundled credit life, well below older effective payouts. ICICI Bank was one of the few large private names in the green, up 0.07% at Rs 1,340.90.

HOW THE PAPER SPLIT THE TAPE

Axis Bank’s drop was its largest in two months. AU Small Finance Bank’s was the largest in six months. About 2.48 million L&T Finance shares changed hands in a block. HDFC Life and ICICI Prudential Life also traded on heavy volume. The advance-decline line at the same snapshot as the Sensex print was 1,383 up, 2,231 down, 169 unchanged.

LIC and SBI Life Trade Higher on Agency Mix

The same draft that crushed open architecture is kinder to tied agents than to banks and brokers. SBI Life’s EoM is already about 10.6% and LIC’s about 11.9%, near or inside the five-year 10-12.5% path. Both names traded higher. Jefferies and HSBC said Star Health is cushioned by an 85% agency mix, and that lower renewal commissions can even help underwriting margins at multi-line general insurers once the first shock passes.

WHO THE BROKER NOTES SHIELD

• LIC: Tied-agency book and an EoM ratio already close to the long-term 10% goal.
• SBI Life: Same lean cost base, plus a higher agency and ULIP mix than private banca-heavy peers.
• Star Health: Agency-led distribution, so the open-architecture cut lands elsewhere.
• ICICI Lombard: Motor own-damage may slow, but acquisition costs should settle once commissions stop racing.

JPMorgan called the near-term effect “topline negative” for insurers and the medium-term effect “constructive” if products get cheaper for buyers. HSBC said HDFC Life and Max Financial face a larger hit than peers as compensation models are rewritten. Max Financial hit the lower circuit at Rs 1,406.70, down 9.99%. The split on the screen was the paper working as designed: pay the person who sells, not the balance-sheet that originates the loan.

NSE Lists at Rs 1,800 on Rival BSE

National Stock Exchange shares listed on BSE at Rs 1,800, a 0.84% premium to the Rs 1,785 issue price, in a Rs 22,569 crore offer for sale that was subscribed 5.71 times. Qualified institutional buyers took 12.68 times their portion; retail took 1.39 times. MD and CEO Ashishkumar Chauhan said more than 34 lakh retail investors were allotted stock and that NSE now has “a family of 36 lakh people.” He also said, “What is good for India is good for NSE.”

Macquarie initiated coverage the same morning. It called NSE “The Dominator,” set an Outperform target of Rs 1,965, about 10% above the issue price, and valued the exchange at 32.5 times FY29 estimated earnings. It expects revenue to grow at a 12% compound rate from FY26 to FY30 and wrote that a full suite of services, technology stack and deep liquidity make NSE “the lynchpin of India’s financialisation.” BSE got Outperform and a Rs 4,000 target as “The Challenger,” yet quoted at Rs 3,229, down 1.27%. MCX, dubbed “The Phoenix,” rose 2.35% to Rs 3,453.40 against a Rs 3,820 target. Groww was initiated Outperform at Rs 260; Angel One Neutral at Rs 285, and the stock was at Rs 293.70, down 1.92%.

The exchange complex is the other side of the same financialisation bet the insurance paper is disciplining. NSE still listed. The muted premium sat below grey-market talk of about 2.2%. The listing did not rescue Bank Nifty.

Aurobindo Hits a Record as Financials Slide

Aurobindo Pharma printed an all-time high of Rs 1,739.30. Laurus Labs hit Rs 2,050.80. Divi’s Laboratories hit Rs 9,631.00. Nifty Pharma was up 0.19% at 27,203.95, with a 19.72% gain year to date. Media was also slightly higher. Almost every other sectoral book was red. India VIX jumped nearly 7%. The US 10-year yield had reached 5.104% on September 23, the highest since July 2007, after hotter business-activity data, a weak five-year auction, and oil near $100. Traders lifted October rate-hike odds to 70% from 55%. Bitcoin fell nearly 4% to $83,881. The Federal Reserve had already raised its range by 25 basis points this month to 3.75-4%.

Those yields explain the global mood and the crypto print. They do not explain why LIC and ICICI Lombard rose while Axis Bank and HDFC Life fell. The domestic event was the commission paper. IRDAI is also building pull infrastructure around the same push crackdown, including Bima Sugam and a public insurance registry proposal meant to let buyers compare and purchase without a hard sell.

About 1,383 shares advanced and 2,231 declined in the snapshot that had the Sensex down 625.52 points. Midcap 150 was off more than 1%. The session billed the 2023 experiment in one tape: aggregators on the circuit, banca banks in the red, agency life and pharma still standing, and the country’s largest exchange listing into that split.

Disclaimer: This article is news reporting and analysis of market moves and a regulatory consultation. It is informational only and is not investment advice, a recommendation to buy or sell any security, or a prediction of how IRDAI will write the final rules. Readers should consult a SEBI-registered investment adviser or other qualified financial professional before acting on any stock, IPO allocation or sector view discussed here. Prices, percentages and the status of the draft reflect the cited sources on September 24, 2026, and can change as the session continues, as comments arrive by October 25, and as any regulation is later notified.